Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therapix Biosciences Ltd ADR TRPX


Primary Symbol: TRPXY

Therapix Biosciences Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several innovative immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The operating segments of the group are Development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the Company's operation); and Pain clinic


OTCPK:TRPXY - Post by User

Comment by Fundy13on Dec 28, 2018 10:33am
35 Views
Post# 29164151

RE:RE:RE:RE:RE:Some tax loss selling?

RE:RE:RE:RE:RE:Some tax loss selling?Really odd takeover.  I am not sure how the company is saying they are paying $11 per share when their share price is about $5 and they are offering 1.5 something shares for each Aphria share, that is about $7.50 or $8 by my math.
But I do believe that meger and aquisition will be the next stage in the sector. 
Tobaco, Alchoal and other large food and beverage companies that are worth hundreads of billions of dollars willl all be looking for a piece of the industry as well as big pharma.  So far investment has come at a nice premium to SP for those companies who have recieved investment and I expect that trend to continue.  Large companies tend to be happy to let the start ups assume the upfront risks and come in when things are more advanced and stable.  But they also do not want to fall behind their cometitors that have already made investments so I expect the next 6-12 months to be full of activity.
<< Previous
Bullboard Posts
Next >>